|
시장보고서
상품코드
2084704
망막정맥폐쇄증 시장 : 질환 종류별, 치료법별, 최종사용자별, 유통 채널별, 지역별Retinal Vein Occlusion Market, By Disease Type, By Treatment Type, By End User, By Distribution Channel, By Geography |
||||||
망막정맥폐쇄증 시장은 2026년에 29억 6,000만 달러 규모가 될 것으로 추정되며, 2033년까지 47억 1,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 6.9%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 29억 6,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 6.90% | 예측 금액(2033년) | 47억 1,000만 달러 |
망막정맥폐쇄증(RVO)은 모든 안구 망막 혈관 질환 중 유병률이 가장 높은 질환 중 하나이며, 전 세계적으로 볼 때 특히 노화에 따른 시력 상실의 주요 원인 중 하나입니다. 망막정맥폐쇄증은 눈의 망막정맥이 막히면서 발생하며, 그 결과 혈류가 저해되어 망막 허혈이나 망막 부종을 유발하고, 적절한 치료를 받지 않을 경우 결국 실명에 이르게 됩니다. 망막정맥폐쇄증은 주로 중심망막정맥폐쇄증(CRVO)과 분지망막정맥폐쇄증(BRVO)이라는 두 가지 하위 유형으로 분류되며, 고혈압, 당뇨병, 고지혈증, 녹내장 등 많은 일반적인 질환과 관련이 있습니다.
세계 인구의 고령화가 급속히 진행되고 있는 데다, 이러한 만성 질환의 유병률이 증가함에 따라 망막정맥폐쇄증으로 인한 전반적인 부담이 커지고 있습니다. 망막정맥폐쇄증의 치료 파이프라인은 항VEGF제, 코르티코스테로이드, 수술, 레이저 치료 등의 치료법에 의해 주도되고 있습니다. 항-VEGF 요법은 망막정맥폐쇄증에 따른 망막부종 치료에 있어 여전히 1차 치료법으로 자리 잡고 있습니다. 이러한 지속적인 혁신에 더해, 장시간 작용형 생물학적 제제 및 그 생물학적 동등성 제품(바이오시밀러)과 같은 신약 개발, 그리고 최첨단 망막 영상 진단 기술의 개발이 진전된 결과, 환자 치료 수준이 향상되었고, 예상보다 빠르게 치료 접근성이 확대되었습니다.
시장 역학
세계 망막정맥폐쇄증 시장은 당뇨병, 고혈압, 심혈관질환의 유병률 증가에 힘입어 성장하고 있습니다. 고령 인구 증가에 더해, 이러한 현상이 망막 혈관과 관련된 질환의 위험 증가에 기여하고 있습니다. 광간섭 단층촬영(OCT) 및 형광 혈관조영술 등의 기술 발전으로 인해 이 질환의 조기 진단이 가능해졌으며, 한편으로는 항VEGF제의 광범위한 적용을 통해 망막정맥폐쇄증에 수반되는 황반부종의 치료에서 양호한 성과를 거두고 있습니다.
그러나 높은 치료비, 반복적인 유리체 내 주사 치료, 코르티코스테로이드 요법으로 인한 부작용 가능성 등 시장에는 몇 가지 제약이 존재합니다. 그럼에도 불구하고, 지속형 약물전달 시스템의 발전, 바이오시밀러의 등장, 그리고 차세대 망막 치료제의 등장은 망막정맥폐쇄증 시장에 새로운 성장 기회를 가져다줄 것입니다.
본 보고서의 주요 특징
- 본 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 시장의 촉진요인 및 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하는 경쟁 전략 등에 관한 중요한 인사이트도 제공하고 있습니다.
- 전 세계 망막정맥폐쇄증 시장의 주요 기업 개요을 각종 지표(기업 개요, 제품 포트폴리오, 주요 동향, 재무 실적, 전략 등)를 바탕으로 수록하고 있습니다.
- 본 보고서의 인사이트를 바탕으로, 마케팅 담당자와 기업 경영진은 향후 제품 출시, 기술 업데이트, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
- '세계 망막정맥폐쇄증 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 재무 분석가 등 이 업계의 다양한 이해관계자들을 대상으로 합니다.
- 이해관계자들은 전 세계 망막정맥폐쇄증 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 망막정맥폐쇄증 시장 : 질환 종류별(2021-2033년)
제5장 세계의 망막정맥폐쇄증 시장 : 치료법별(2021-2033년)
제6장 세계의 망막정맥폐쇄증 시장 : 최종사용자별(2021-2033년)
제7장 세계의 망막정맥폐쇄증 시장 : 유통 채널별(2021-2033년)
제8장 세계의 망막정맥폐쇄증 시장 : 지역별(2021-2033년)
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고문헌과 분석 방법
KSM 26.07.16Retinal Vein Occlusion Market is estimated to be valued at USD 2.96 Bn in 2026 and is expected to reach USD 4.71 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.96 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.90% | 2033 Value Projection: | USD 4.71 Bn |
Retinal vein occlusion (RVO) is one of the most prevalent of all ocular retinal vascular diseases, and is one of the predominant causes of visual loss worldwide especially the age-related loss of vision. Retinal vein occlusion is caused by the occlusion of an eye's retinal veins, resulting in the disruption of circulation and subsequently leads to ischemia of retina, retinal edema, and eventually blindness if not appropriately treated. Retinal vein occlusion can be classified into two primary subtypes, central RVO (CRVO) and branch RVO (BRVO) and is linked with a number of prevalent conditions namely hypertension, diabetes, hyperlipemia, and glaucoma.
Rapid global aging population along with rising prevalence of these chronic illnesses are adding to the overall burden of retinal vein occlusion. The retinal vein occlusion treatment pipeline is driven by modalities including anti-VEGF agents, corticosteroids, surgery, and laser therapy. Anti-VEGF therapies continue to be the first choice for treating retinal edema linked with retinal vein occlusion. These ongoing innovations, together with emergence of newer drug development as long-acting biologic drugs and their bioequivalents/biosimilars, development of state-of-the-art retinal imaging techniques have resulted in higher standards for patient treatment and broadened accessibility to the therapy over the anticipated timeframe.
Market Dynamics
The global retinal vein occlusion market is driven by rising prevalence of diabetes, hypertension and cardio vascular diseases. In addition to a growing geriatric populace, this phenomenon contributed towards increasing risks of the diseases related to retinal vessels. Technology advancements such as in optic coherence tomography (OCT) and fluorescence angiography are enabling better early prognosis of the condition, whilst broad application of anti-VEGF drugs have led to successful treatment results in the retinal vein occlusion linked macular oedema.
However, a number of constraints are present in the market, such as high treatment cost, repetitive intra vitreal injection treatments and probable side-effects by corticosteroid therapies. Nevertheless, advancements in long-acting drug delivery systems, the emergence of biosimilars, and the next generation retinal therapeutics will offer new opportunities for growth in the retinal vein occlusion market.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global retinal vein occlusion market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Bayer AG, AbbVie Inc., Biogen Inc., Samsung Bioepis, Sandoz Inc., Biocon Biologics, Amgen Inc., and Alimera Sciences
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global retinal vein occlusion market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global retinal vein occlusion market
Market Segmentation
- Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
- Central Retinal Vein Occlusion (CRVO)
- Branch Retinal Vein Occlusion (BRVO)
- Treatment Type Insights (Revenue, USD Bn, 2021 - 2033)
- Anti-VEGF Therapy
- Corticosteroid Therapy
- Laser Therapy
- Others
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Ophthalmology Clinics
- Ambulatory Surgical Centers (ASCs)
- Others
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Regeneron Pharmaceuticals
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- AbbVie Inc.
- Biogen Inc.
- Samsung Bioepis
- Sandoz Inc.
- Biocon Biologics
- Amgen Inc.
- Alimera Sciences
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Retinal Vein Occlusion Market, By Disease Type
- Global Retinal Vein Occlusion Market, By Treatment Type
- Global Retinal Vein Occlusion Market, By End User
- Global Retinal Vein Occlusion Market, By Distribution Channel
- Global Retinal Vein Occlusion Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Disease Type Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Industry Trends
4. Global Retinal Vein Occlusion Market, By Disease Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Central Retinal Vein Occlusion (CRVO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Branch Retinal Vein Occlusion (BRVO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Retinal Vein Occlusion Market, By Treatment Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Anti-VEGF Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Corticosteroid Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Laser Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Retinal Vein Occlusion Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Ophthalmology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Retinal Vein Occlusion Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Specialty Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Retinal Vein Occlusion Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Regeneron Pharmaceuticals
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-La Roche Ltd.
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen Inc.
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Samsung Bioepis
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sandoz Inc.
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biocon Biologics
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alimera Sciences
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
